Eli Lilly is launching the Zepbound obesity medication pen in single monthly doses

Eli Lilly Zibbond on Monday launched a new form of the blockbuster obesity drug, which delivers a month’s worth of doses in one pen.

Patients paying cash can get the multi-dose device, called the KwikPen, on the company’s direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level.

A pen can be a more convenient option for some patients, because it reduces the number of devices they have to use during a month to take the medication. Patients can use one pen to take four weekly doses of Zepbound.

Currently, patients undergoing treatment use a different self-injection device for one dose each week. Lilly also offers single-dose vials of Zepbound, which require users to draw the medication into a syringe and inject themselves.

The announcement comes as Lilly works to maintain the early success of Zepbound, which has been in growing demand since it first entered the market in late 2023. LillyDirect has been key to Zepbound’s growth, and bringing a new form of the drug to the platform could attract more patients.

Zepbound’s rapid growth helped Eli Lilly seize a majority share of the weight-loss drug market from rival Novo Nordisk. In the company’s fourth quarter, Zepbound generated revenue of $4.2 billion, up 122% from the previous year.

The FDA has approved expanding Zepbound’s label to include the multi-dose device, Lilly said in a statement.

The KwikPen is already used in other medications, such as Lilly’s popular diabetes drug Mounjaro.

“As part of our commitment to supporting people with obesity on their weight management journey, we are offering a new option with the Zepbound KwikPen, a device trusted by patients globally and in the U.S. for other Lilly medications,” Ilya Yuva, Lilly’s president of U.S. and global customer capabilities, said in the release.